213 related articles for article (PubMed ID: 33026311)
1. Emotional and interpersonal mechanisms in community SSRI treatment of social anxiety disorder.
Rappaport LM; Hunter MD; Russell JJ; Pinard G; Bleau P; Moskowitz DS
J Psychiatry Neurosci; 2021 Jan; 46(1):E56-E64. PubMed ID: 33026311
[TBL] [Abstract][Full Text] [Related]
2. Affect, interpersonal behaviour and interpersonal perception during open-label, uncontrolled paroxetine treatment of people with social anxiety disorder: a pilot study.
Rappaport LM; Russell JJ; Hedeker H; Pinard G; Bleau P; Moskowitz DS
J Psychiatry Neurosci; 2018 Nov; 43(6):407-415. PubMed ID: 30375835
[TBL] [Abstract][Full Text] [Related]
3. Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial.
Faria V; Gingnell M; Hoppe JM; Hjorth O; Alaie I; Frick A; Hultberg S; Wahlstedt K; Engman J; Månsson KNT; Carlbring P; Andersson G; Reis M; Larsson EM; Fredrikson M; Furmark T
EBioMedicine; 2017 Oct; 24():179-188. PubMed ID: 29033138
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
[TBL] [Abstract][Full Text] [Related]
5. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with paroxetine in social anxiety disorder.
Baldwin DS
Int Clin Psychopharmacol; 2000 Jul; 15 Suppl 1():S19-24. PubMed ID: 10994679
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.
Stein DJ; Versiani M; Hair T; Kumar R
Arch Gen Psychiatry; 2002 Dec; 59(12):1111-8. PubMed ID: 12470127
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders.
Jakubovski E; Johnson JA; Nasir M; Müller-Vahl K; Bloch MH
Depress Anxiety; 2019 Mar; 36(3):198-212. PubMed ID: 30479005
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on paroxetine in psychiatric disorders in adults.
Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
[TBL] [Abstract][Full Text] [Related]
10. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
Stein MB; Liebowitz MR; Lydiard RB; Pitts CD; Bushnell W; Gergel I
JAMA; 1998 Aug; 280(8):708-13. PubMed ID: 9728642
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
Liebowitz MR; Gelenberg AJ; Munjack D
Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
[TBL] [Abstract][Full Text] [Related]
12. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
Pini S; Amador XF; Dell'Osso L; Baldini Rossi N; Cassano P; Savino M; Cassano GB
Int Clin Psychopharmacol; 2003 Jan; 18(1):15-21. PubMed ID: 12490770
[TBL] [Abstract][Full Text] [Related]
13. Selective alteration of personality and social behavior by serotonergic intervention.
Knutson B; Wolkowitz OM; Cole SW; Chan T; Moore EA; Johnson RC; Terpstra J; Turner RA; Reus VI
Am J Psychiatry; 1998 Mar; 155(3):373-9. PubMed ID: 9501748
[TBL] [Abstract][Full Text] [Related]
14. Neural correlates of explicit and implicit emotion processing in relation to treatment response in pediatric anxiety.
Burkhouse KL; Kujawa A; Klumpp H; Fitzgerald KD; Monk CS; Phan KL
J Child Psychol Psychiatry; 2017 May; 58(5):546-554. PubMed ID: 27861879
[TBL] [Abstract][Full Text] [Related]
15. Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy.
Hjorth O; Frick A; Gingnell M; Engman J; Björkstrand J; Faria V; Alaie I; Carlbring P; Andersson G; Jonasson M; Lubberink M; Antoni G; Reis M; Wahlstedt K; Fredrikson M; Furmark T
Transl Psychiatry; 2022 Oct; 12(1):436. PubMed ID: 36202797
[TBL] [Abstract][Full Text] [Related]
16. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder.
Stein DJ; Stein MB; Goodwin W; Kumar R; Hunter B
Psychopharmacology (Berl); 2001 Nov; 158(3):267-72. PubMed ID: 11713616
[TBL] [Abstract][Full Text] [Related]
17. Do venlafaxine XR and paroxetine equally influence negative and positive affect?
Dichter GS; Tomarken AJ; Freid CM; Addington S; Shelton RC
J Affect Disord; 2005 Apr; 85(3):333-9. PubMed ID: 15780704
[TBL] [Abstract][Full Text] [Related]
18. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine in social anxiety disorder: a randomized placebo-controlled study.
Allgulander C
Acta Psychiatr Scand; 1999 Sep; 100(3):193-8. PubMed ID: 10493085
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for social anxiety disorder (SAnD).
Williams T; Hattingh CJ; Kariuki CM; Tromp SA; van Balkom AJ; Ipser JC; Stein DJ
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001206. PubMed ID: 29048739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
